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There is a strong association between both acute and chronic dysfunction of the heart and kidneys with respect to morbidity
and mortality. The complex interrelationships of longitudinal changes in both organ systems have been diﬃcult to describe and
fully understand due to a lack of categorization of the common clinical scenarios where these phenomena are encountered. Thus,
cardiorenal syndromes(CRSs)havebeen subdivided into ﬁve syndromes which represent clinicalvignettes in which both the heart
andthekidneyareinvolvedinbidirectionalinjuryanddysfunctionviaaﬁnalcommonpathwayofcell-to-cell deathandaccelerated
apoptosis mediated by oxidative stress. Types 1 and 2 involve acute and chronic cardiovascular disease (CVD) scenarios leading to
acute kidney injury (AKI) oraccelerated chronickidney disease(CKD). Types 3and 4describe AKI andCKD, respectively, leading
primarily to heart failure, although it is possible that acute coronary syndromes, stroke, and arrhythmias could be CVD outcomes
in these forms of CRS. Finally, CRSs type 5 describe a systemic insult to both heart and the kidneys, such as sepsis, where both
organs are injured simultaneouslyin persons with previously normalheart and kidney function at baseline. Both blood and urine
biomarkers, including the assessment of catalytic iron, a critical element to the generation of oxygen-free radicals and oxidative
stress, are reviewed in this paper.
1.Introduction
The worldwide pandemicofexcessadiposity isthe “common
soil” for mutual risk factors leading to cardiovascular disease
(CVD) and chronic kidney disease (CKD) including the
metabolic syndrome, diabetes, hypertension, dyslipidemia,
neurohormonalactivation,and systemic inﬂammation. Both
cardiac and renal diseases commonly present in the same
patient and have been associated with increased cost of
care, complications, and mortality [1, 2]. There is an
immediate and present need to categorize the complex
relationships between acute and chronic organ injury and
dysfunction that exist with respect to the heart and kidneys.
The cardiorenal syndromes (CRSs) describe the dynamic
interrelationship between heart and kidney malfunction
and have been clariﬁed in a recent consensus eﬀort led
by the Acute Dialysis Quality Initiative (ADQI) [3]. Five
distinct CRSs have been proposed. This paper will review
this new classiﬁcation scheme and giving vignettes of each
syndrome discuss available information on recognition and
management. In addition, a targeted review of promising
biomarkers will be presented. It is expected that these
biomarkers will considerably enhance the current body of
literature concerning CRSs which is largely based on single
blood biomarker—serum creatinine and its derivative, the
estimated glomerular ﬁltration rate (eGFR).
2. Five CardiorenalSyndromes
The plural term CRSs suggests several subtypes denoted
by the principal organ dysfunction by temporal sequence
(cardiac versus renal or simultaneous) as well as the relative
acuity of each illness. Both organs must have or develop evi-
dence of pathological changes to fulﬁll the criteria for deﬁni-
tion. The umbrella term“cardiorenal syndromes” was deﬁned
as “Disorders of the heart and kidneys whereby acute or
chronic dysfunction in one organ may induce acute or
chronic dysfunction of the other” [3]. Figure 1 displays
an array of possible pathophysiologic mechanisms for each2 International Journal of Nephrology
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Figure 1: Pathophysiology and deﬁnitions of the ﬁve subtypes of cardiorenal syndromes.International Journal of Nephrology 3
syndrome. As shown, it has been recently understood that
the process of oxidative stress resulting in cell dysfunction,
accelerated apoptosis, and death is reliant on the cytosolic
andextracellularpresenceoflabileorcatalyticiron.Thereare
several steps in generation of reactive oxygen species (ROS).
Oxygen may be reduced forming superoxide anion, which
can undergo reduction by superoxide dismutase to form
hydrogen peroxide which itself can then be reduced through
severalpathways.The net reaction is slowand in thepresence
of reduced transition metals such as ferric iron (Fe+3), a
Haber-Weiss reaction results in the rapid formation of the
highlydamaginghydroxylradicalfromthesuperoxideanion.
Likewise, in the presence of ferrous iron (Fe+2), a Fenton-
type reaction converts hydrogen peroxide to the hydroxyl
radical. Thus, the presence of labile iron, in excess both in
the cytosol and in the extracellular space, could result in
the generation of the hydroxyl radical which further causes
destruction of cellular organelles and membranes. Further
reduction of hydroxyl radical ﬁnally ends in the formation
of water. It has been theorized that a common element to all
forms of oxidative stress to the heart and kidneys involves
the periodic availability of unbound or poorly liganded
iron [4]. There is a complex management system for iron
metabolism keeping it bound in transport proteins, heme,
and cellular organelles for normal functioning [5, 6]. If
small amounts of iron are released from adjacent injured
cells and not immediately bound, this poorly liganded
(labile or catalytic) iron in either the ferric or ferrous states
facilitates the rapid generationo fo x y g e n - f r e er a d i c a l sa n d
the propagation of oxidative stress and injury across regions
of vascular tissue [7]. Therefore, a putative ﬁnal common
pathway for common sources of organ injury resulting
in CRSs including ischemia, neurohormonal activation,
chemotoxicity, and sepsis involves the loss of control over
normal iron management and the transient tissue and organ
system exposure to catalytic iron.
2.1. Acute Cardiorenal Syndrome (Type 1): Acute Cardiac
Event Precipitating AKI. This is a syndrome of worsening
renal function that frequently complicates acute decompen-
sated heart failure (ADHF) and acute coronary syndrome
(ACS). Seven observational studies have reported on the
frequency and outcomes of CRSs Type 1 in the setting of
ADHF and ﬁve in ACS [8]. Approximately one-third of
patients hospitalized for ADHF develop acute kidney injury
(AKI) as deﬁned by an increase in serum creatinine of
≥0.3mg/dl [8, 9]. Baseline CKD, diabetes, prior HF, and ini-
tial presentation with hypertension are established risk pre-
dictors for CRSs Type 1 [10]. Complicated hospital courses
with hemodynamic decompensation, longer inpatient stays,
and higher mortality have all been consistently described
with CRSs Type 1. However, part of this relationship can
be attributed to confounding by temporal association as
observedbytheProspectiveOutcomesStudyinHeartFailure
(POSH) study, where only ADHF cases with a rise in
serum creatinine (≥0.3mg/dl) who concurrently developed
hemodynamic compromise, cardiac arrest, infection, or
acute coronary ischemia were observed to have a higher
six-month mortality [11]. Conversely, those with a similar
rise in serum creatinine but no other complications did not
incur higher death rates in the hospital, at 30 or 180days
compared to those without such a rise in creatinine. Because
CRSs Type 1 in patients with heart failure rarely occurs
in the prehospital phase and more commonly develops
after treatment is started in hospital, iatrogenic factors have
been implicated. The use of loop diuretics, probably by
further activating the renin-angiotensin system and possibly
worsening intrarenal hemodynamics, has been identiﬁed as
one of the modiﬁable in-hospital determinants of CRSs
Type 1 [12]. In the Evaluation Study of Congestive Heart
Failure and Pulmonary Artery Catheterization Eﬀectiveness
(ESCAPE) trial, the use of higher doses of loop diuretics,
causing hemoconcentration, resulted in a 5-fold increased
rate of worsening renal function [13]. However, it should be
noted despite these observations that aggressive diuresis was
associated with a 69% reduction in death at 180days. The
presence of an elevated central venous pressure and inferred
renal venous congestion, as opposed to hypotension or poor
cardiac output, has been associated with the development
of CRSs Type 1. The relative balance of arterial and venous
pressure, volume, and ﬂow resulting in congestion of the
kidney appear to be important in the drop in renal ﬁltration
that occurs during acute treatment of AHDF [14].
Another scenario where CRSs Type 1 has been described
is in the setting of coronary revascularization proce-
dures. Acute contrast-induced and cardiopulmonary bypass
surgery-associated AKI has been reported in approximately
15 and 30% of patients, respectively [15, 16]. Iodinated con-
trast causes transient renal vasoconstriction, and medullary
hypoxia and is directly chemotoxic to renal tubular cells.
Its use is the primary cause of AKI in the setting of ACS
and elective coronary catheter-based procedures. In addi-
tion, contrast-induced acute kidney injury (CI-AKI) is an
important pre-existing factor in the prior days before cardiac
surgery rendering patients at risk for further renal injury
with cardiopulmonary bypass. Cardiac surgery exposes the
kidneys to hypothermic, pulseless reduced perfusion for 30–
90minutes and results in reduced renal perfusion in the
setting of a proinﬂammatory state [17]. The extracorporeal
circuit used in cardiopulmonary bypass surgery activates
systemic factors and may release catalytic iron from heme,
which works to induce AKI in the setting of reduced
temperatureandﬂowtothekidneys[18].Reducingexposure
to the perfusion circuit has not resulted in reduced rates
of AKI but has attenuated its severity [19]. Contrast-
induced AKI and cardiac surgery-associated AKI are in
a temporal pathophysiologic sequence since almost every
cardiac surgery patient operated upon in the urgent setting
undergoes coronary angiography in the hours to days
before surgery [20]. Similar to ADHF, patients undergoing
revascularization with complications, CRSs Type 1 appears
to be independently associated with a 3- to 4-fold increase
in mortality irrespective of the use of renal replacement
therapy [21, 22]. In all forms of CRSs Type 1, there is a
risk of advancing to higher stages of CKD and end-stage
renal disease (ESRD) [23]. The incremental and cumulative
risk of these renal outcomes in patients undergoing multiple4 International Journal of Nephrology
coronary revascularization procedures over a lifetime is not
known. Salient features of CRSs Type 1 described in the
literature to date include (1) higher mortality risk can
be attributed to nonrenal complications (shock, infection,
and arrhythmias) occurring during the hospitalization and
not the rise in creatinine itself, (2) intravascular iodinated
contrast alone, and in conjunction with cardiopulmonary
bypass, initiates AKI via a transient reduction in renal blood
ﬂowandmedullaryhypoxiafollowedbydirectchemotoxicity
to renal tubular cells, and (3) during ADHF hospitalization,
the use of iodinated contrast or other cardiac procedures is
associated with longer lengths of stay and higher mortality
which ispossiblyin partattributabletoCRSsType1[24–26].
Preventive Approaches. It is beyond the scope of this paper
to review the body of clinical trials that have attempted to
reducecontrast-inducedand cardiacsurgery-associated AKI.
The basic principles include avoidance of volume depletion,
removal of superimposed renal toxic agents (nonsteroidal
anti-inﬂammatory agents, aminoglycosides), minimization
of the toxic exposure (iodinated contrast, time on cardiopul-
monary bypass), and possibly the use of antioxidant agents
such as N-acetylcysteine (for contrast exposure) and B-type
natriuretic peptide in the perioperative period after cardiac
surgery [27, 28]. More broadly across all forms of CRSsType
1, consideration should be given for forms of continuous
renal replacement therapy (CRRT) in the period of time
surrounding the renal insult. Conceptually, the use of CRRT
providesthree important protective mechanisms thatcannot
be achieved pharmacologically as follows: (1) it ensures
euvolemia and avoids hypo- or hypervolemia, (2) it provides
sodium and solute (nitrogenous waste products) removal,
and (3) by both mechanisms above, it may work to avoid
both passive renal congestion and a toxic environment for
the kidneys and allow their optimal function during a sys-
temically vulnerable period [29]. Despite these advantages,
there remains a lack of clinical trial data supporting CRRT
over other forms of extracorporeal solute removal. Finally,
for patients in whom anuria and serious renal failure have
a high probability of occurring, the upstream use of CRRT
removes the hazards around the critical period of initiation
of dialysis including electrolyte imbalance, urgent catheter
placement, and extreme volume overload.
2.2. Chronic Cardiorenal Syndrome (Type 2): Chronic CVD
Leading to Progressive CKD. It is important to recognize that
chronic CVD in some cases leads to the progression of CKD.
Observational studies have suggested that CVD contributes
to an excess risk of CKD and its progression (CRSs Type 2)
[8]. The established risk factors for atherosclerosis, namely
diabetes,hypertension, and smoking are independentlyasso-
ciated with the development of CKD [30]. Left ventricular
systolic and diastolic dysfunction can lead to alterations
in neurohormonal activation, renal hemodynamics, and a
variety of adverse cellular processes leading to apoptosis
and renal ﬁbrosis [31]. One-third of the prevalent pool of
CVD has concurrent CKD and, when combined, leads to
further disease progression [29]. In the National Kidney
Foundation, Kidney Early Evaluation Program, CKD has
been associated with premature CVD events including MI
and stroke [32, 33]. Chronic kidney disease-associated bone
and mineral disorder characterized by phosphate retention,
relative vitamin D deﬁciency and calcium availability, and
secondary hyperparathyroidism is pathophysiologylinked to
the accelerated calciﬁc atherosclerosis observed in patients
with CKD [34]. Hyperphosphatemia, due to phosphate
retention, stimulates the conversion of vascular smooth
muscle cells to osteoblastic-like cells which, via the Pit-1
receptor, are stimulated to produce extracellular calcium
hydroxyapatite crystals in the vascular smooth muscle layer
of atherosclerotic arteries [35, 36] .T h u s ,p a t i e n t sa sap a r t
of CRSs type 2 more commonly have vascular calciﬁcation,
less vascular compliance, and a higher degree of chronic
organ injury due to shear stress at the large, medium,
and smaller vessel levels [37]. Despite these mechanisms
speciﬁc to CRSs, CRSs Type 2 remains heavily confounded
by the “common soil” of atherosclerosis and CKD. Excess
adiposity and the cardiometabolic syndrome with activation
of the sympathetic and renin-angiotensin systems as well
as adipokine-stimulated systemic inﬂammation aﬀect both
organ systems; therefore, it is likely that for most patients
with CRSs Type 2, concurrent organ injury is occurring
based on these pathophysiologic mechanisms [38].
Approximately half of chronic HF patients have evidence
of CKD deﬁned as an estimated glomerular ﬁltration rate
(eGFR) <60ml/min/1.73m2[39] .T h ep r e s e n c eo fC K Dh a s
been associated with more frequent hospitalizations and
death from pump failure and arrhythmias [40, 41]. Sodium
and water retention are the primary cardiac insults put
f o r w a r da st oh o wC K Dw o r s e n sH F .I ts h o u l da l s ob e
mentioned that CKD is associated with diuretic resistance
and higher rates of drug intolerance to inhibitors of the
renin-angiotensin-aldosterone system. Patients with CKD
and ESRD have greater risks of ventricular arrhythmias and
higher deﬁbrillation thresholds; thus, they may have higher
failure rates of antiarrhythmic therapy and implantable
cardiodeﬁbrillators [42]. Greater left ventricular mass and
cardiac ﬁbrosis may be responsible electrophysiological
ﬁndings in patients with CKD [43]. Finally, asymptomatic
cerebral infarctions by magnetic resonance imaging have
been associated with a rapid decline in renal function
in approximately 30% of patients [44]. This suggests the
possibility that systemic atherosclerosis contributes to more
rapid progression of CKD. Future research on the systemic
and direct eﬀects of atherosclerosis on the kidney is needed.
Preventive Approaches. As a general axiom, pharmacologic
therapies that have been beneﬁcial for chronic CVD have
been either neutral or favorable to the kidneys including use
of renin angiotensin aldosterone system (RAAS)antagonists,
beta-adrenergic blocking agents, and statins. Furthermore,
other strategies which are modestly beneﬁcial from a cardiac
perspective have even a larger beneﬁt on microvascular
injury to the kidneys including glycemic control in diabetes
and blood pressure control in those with hypertension
[45]. Finally, there is some support from clinical trials that
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microalbuminuria in patients with CKD. The long-term
clinicalimplications oftheseobs ervationsar eunkno wn[46].
2.3. AcuteCardiorenal Syndrome (Type 3): AcuteWorsening of
Renal Function Leading to Cardiac Events. A well-described
vignette for CRSsType 3 is the developmentof AKI resulting
in volume overload, sodium retention, neurohormonal acti-
vation, and ADHF with the cardinal features fatigue, breath-
lessness, and peripheral edema. In children, isolated volume
overload has been shown to induce myocardial dysfunction
and CRSs Type 3 [47]. The picture is not so clear in adults,
when acute on chronic disease is a frequent paradigm. It is
conceivable that CRSs Type 3 could precipitate ACS, stroke,
or other acute cardiac event; however, the epidemiological
evidenceandpathophysiologicalbasisareyettobedescribed.
In summary, CRSs Type 3 is not well deﬁned for individual
CVD events such as ACS, stroke, cardiac rehospitalization,
arrhythmias, pump failure, and cardiac death and thus is a
futureresearch topicin termsofdescribingthe epidemiology
and pathogenesis of this syndrome [8].
Preventive Approaches. The major management principle
concerning this syndrome is intra- and extravascular volume
control with either use of diuretics and forms of extracor-
poreal volume and solute removal (CRRT, ultraﬁltration,
hemodialysis). In the setting of AKI, prevention of left
ventricular volume overload is critical to maintain adequate
cardiac output and systemic perfusion and avoid the viscous
downward spiral in both cardiac and renal function.
2.4. Chronic Cardiorenal Syndrome (Type 4): CKD Leading
to the Progression of CVD and Death. There is a graded
and independent association between the severity of CKD,
assessed by baseline eGFR, and incident as well as prevalent
CVD [2]. A meta-analysis of 39 studies (1,371,990 partici-
pants)found asigniﬁcant, independentrelationship between
the severity of CKD and the risk for all-cause death [48]. In
this review, cardiovascular deaths constituted over 50% of
fatalities. Thirteen studies have reported on the occurrence
of CRSs Type 4 mainly in populations with ESRD on dialysis
[8]. In this scenario, decreased renal function inﬂuences
C V Do u t c o m e si nC R S sT y p e4b ym a k i n gc o n v e n t i o n a l
management ofCADorHFmore diﬃcult[49,50].Azotemia
and hyperkalemia are known to limit the use of drugs that
antagonize the renin-angiotensin aldosterone system; thus,
fewer patients with CKD enjoy the cardiovascular beneﬁts
of angiotensin converting enzyme inhibitors, angiotensin II
receptor antagonists, and aldosterone receptor blockers [51,
52]. The presence of CKDalso increases the severity,worsens
theresponsetotreatment,andisassociatedwithpoorcardiac
and renal outcomes in acute and chronic hypertension [53,
54].Amongstclinicians,theperceivedrisksofAKIinpatients
withCKDgenerallyproducemoreconservativemanagement
strategies which have been associated with poor outcomes in
the setting of ACS and stable CVD [55].
Preventive Approaches. Optimal treatment of CKD with
blood pressure and glycemic control, RAAS blockers, and
disease-speciﬁc therapies,when indicated,are thebestmeans
of preventing this syndrome. Morbidities of CKD, including
bone and mineral disorder and anemia, should be managed
according to CKD guidelines; however, clinical trials have
failed to demonstrate that treatment of these problems
inﬂuences CVD outcomes [56, 57].
2.5. Secondary Cardiorenal Syndrome (Type 5): Systemic
Illness Leading to Simultaneous Heart and Renal Failure. It is
recognized that a systemic insult, particularly in a younger
patient with no prior heart or kidney disease, can lead to
simultaneous organ dysfunction. This is almost always in
the setting of critical illness such as sepsis, multiple trauma,
or burns and can be thought of being part of multiorgan
system failure. There are limited data on the incidence and
determinants of CRSs (Type 5) in part because confounders
such as hypotension, respiratory failure, liver failure, and
other organ injury beyond the cardiac and renal systems
create a diﬃcult human model for investigation. Sepsis as
a precipitator of CRSs Type 5 is common, and its incidence
is increasing, with a mortality estimated between 20% and
60% [58–60]. Approximately 11–64% of septic patients
develop AKI that is associated with a higher morbidity and
mortality [61]. Abnormalities in cardiac function are also
common in sepsis including wall motion abnormalities and
transient reductions in left ventricular ejection fraction [62].
Observational data have found approximately 30–80% of
individuals with sepsis have measurable blood troponin I
or T that elevates above the 99th detection limits [63].
These elevated cardiac biomarkers have been associated
with reduced left ventricular function and higher mortality
even in patients without known coronary disease [64, 65].
Importantly, volume overload as a result of aggressive ﬂuid
resuscitation appears to be a signiﬁcant determinant of CRSs
Type 5. Among the 3,147 patients enrolled in the Sepsis
Occurrence in Acutely Ill Patients (SOAP), there was a 36%
incidence of AKI, and volume overload was the strongest
predictor of mortality [66]. Iatrogenic volume overload
appears to play an important additional role, possibly along
the lines described for CRSs Type 1 and passive venous
congestion of the kidney, in the pathogenesis of AKI. At the
same time, volume overload increases left ventricular wall
tension and likely contributes to cardiac decompensation in
those predisposed to both systolic and diastolic HF [67].
In summary for CRSs Type 5, both AKI and markers of
cardiac injury followed by volume overload are common in
sepsis, with each being associated with increased mortality.
However, there is a current lack of integrative information
on the incidence of bidirectional organ failure and its
pathophysiological correlates in a variety of acute care
settings.
Preventive Approaches. There are no proven methods to
prevent or ameliorate this form of CRSs at this time.
Randomized trials of early versus later intervention with
CRRT have shown no diﬀerential beneﬁt. Supportive care
with a judicious intravenous ﬂuid approach and the use of
pressor agentsas needed toavoidhypotension are reasonable
but cannot be expected to avoidAKI or cardiac damage [68].6 International Journal of Nephrology
3.Biomarkersof CardiorenalSyndromes
There is considerable interest in blood and urine biomarkers
to detect CRSs. For decades, ther i s ei ns e r u mc r e a t i n i n eh a s
been the only detectable sign of a reduction in glomerular
ﬁltration. Creatinine has had the disadvantages of being
linked to creatine and the overall body muscle mass, hence,
diﬀering according to body size in addition to the rate of
renal elimination [69]. Furthermore, the kidney both ﬁlters
and secretes creatinine. Finally, the assays used to measure
creatinine have not been standardized across laboratories;
therefore, studies reporting values from multiple centers
have inherent variation in values attributed to diﬀerences in
measurement technique [70]. Hence, there is a clear need for
better laboratory markers of renal ﬁltration. An ideal marker
would be independent of muscle mass, reﬂect actual renal
ﬁltration as the time it was measured, and be sensitive to
changes in actual glomerular ﬁltration rate (GFR) in order
to signal clinicians to a meaningful change shortly after it
occurs.
Unlike cardiac biomarkers indicating myocardial injury
and overload (troponin, creatine kinase myocardial band,
and natriuretic peptides), the ﬁeld of nephrology has been
devoidofapprovedblood orurine markers ofAKI.Thus, the
current paradigm is that when renal injury occurs, clinicians
must wait to observe a reduction in GFR before AKI is
inferred. The concept of measuring makers of the acute
injury process is crucial to the early upstream identiﬁcation
of AKI before there is serious loss of organ function [71].
Below is a summary of relatively novel renal markers and
what is known about them in acute cardiac and renal injury.
Their use in the years to come will undoubtedly inﬂuence
the epidemiology of CRSs. However, there are pitfalls to the
widespread use of novel biomarkers including inappropriate
conclusions along all lines of clinical decision making. Thus,
considerable data are needed before any new marker enters
the clinical arena.
3.1. Catalytic Iron. Iron is the most common metal element
in the human body, and there are elaborate transport and
management systems for its usein a variety ofcriticalcellular
systems including oxygen transport and cellular respiration.
It has been known that poorly liganded iron is the critical
basis for the generation of the hydroxyl radical, which is
the most destructive of all reactive oxygen species. Using
the bleomycin detectable assay, Lele and coworkers have
recently demonstrated the release of catalytic iron into the
bloodinpatientswithacutecoronarysyndromes[72].Inthis
study, the appearance of catalytic iron preceded the rise in
serum troponin andhad an area underthereceiver operating
characteristic curve for the detection of acute myocardial
infarction over 0.90. Labile iron is also believed to play
an essential role in the oxidative organ damage of AKI as
discussed above [73]. It is believed that local cellular and
tissue availability of catalytic iron determines the degree and
severity of organ injury in the setting of most hypoxic and
othertoxicinsults[74].Thus,catalyticironmayserveasboth
a diagnostic and therapeutic target by using iron chelators in
the future for CRSs [75].
3.2. Neutrophil Gelatinase-Associated Lipocalin (NGAL).
Siderocalin, or NGAL, was originally identiﬁed as a 25kDa
protein which is a natural siderophore which works to
scavenge cellular and pericellular labile iron, and thus,
reducing its availability for bacterial growth. By reducing the
availability of poorly liganded Fe(II) and Fe(III), which are
needed to catalyze the Haber-Weiss and Fenton equations
in the generation of reactive oxygen species, NGAL appears
to have an important role in limiting oxidative damage in
both acute and chronic diseases. NGAL seems to be one
of the earliest kidney markers of ischemic or nephrotoxic
injury in animal models, and it may be detected in the blood
and urine of humans soon after AKI. Several studies have
conﬁrmed these ﬁndings; in intensive care adult patients
with AKI secondary to sepsis, ischemia, or nephrotoxins,
NGAL is signiﬁcantly increased in the plasma and urine
when compared to normal controls [76].
3.3. Cystatin C. Cystatin C is a cysteine protease inhibitor
that is synthesized and released into the blood at a relatively
constant rate by all nucleated cells. It is freely ﬁltered by the
glomerulus, completely reabsorbed by the proximal tubule,
and not secreted into urine. Its blood levels are not aﬀected
by age, gender, race, or muscle mass; thus, it appears to
be a better predictor of glomerular function than serum
creatinine in patients with CKD. In AKI, urinary excretion
of cystatin C has been shown to predict the requirement
for renal replacement therapy earlier than creatinine. Finally,
cystatin C has consistently outperformed serum creatinine
a n de G F Ri nt h er i s kp r e d i c t i o nf o re v e n t si np a t i e n tw i t h
CVD [77].
3.4. Kidney Injury Molecule 1 (KIM-1). Kidney Injury
Molecule 1 (KIM-1) is a transmembrane glycoprotein which
isnotnormallydetectableinurine[78].KIM-1ismeasurable
in the urine after ischemic or nephrotoxicinsults to proximal
tubular cells [79]. Urinary KIM-1 seems to be highly speciﬁc
for AKI due to systemic illnesses such as sepsis and not for
prerenalazotemia ordrug-inducedrenal injury.Importantly,
KIM-1 may be elevated before there is histologic evidence of
proximal tubular cell death [44].
3.5. N-Acetyl-β-(D)Glucosaminidase (NAG). Recognized
over thirty years ago, NAG is a lysosomal brush border
enzyme found in proximal tubular cells. It is a large
protein (>130kD) and is therefore not ﬁltered through the
glomerular membrane. NAG has been shown to function
as a marker of AKI, reﬂecting particularly the degree of
tubular damage. It is not only found in elevated urinary
concentrations in AKIand CKDbutalso in diabetic patients,
patients with essential hypertension and heart failure [80].
3.6. Interleukin-18 (IL-18). IL-18 is a proinﬂammatory
cytokine detected in the urine after acute ischemic proximal
tubular damage [81]. It displays sensitivity and speciﬁcity
for ischemic AKI with an area under the receiver operating
characteristic curve of >90% with increased levels 48hours
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with AKI mortality, but like other interleukins, it is not
organ speciﬁc. IL-18 has also been theorized to participate in
myocardial cell damage in the setting of ACS, and inhibitors
of IL-18 expressed by stem cells have been shown to be
protective in models of myocyte injury [82].
3.7. Liver Fatty Acid-Binding Protein (L-FABP). Liver fatty
acid-binding protein (L-FABP) binds selectively to intra-
cellular free unsaturated fatty acids and lipid peroxidation
products during hypoxic tissue injury and is found in
the urine of patients with AKI [83]. Urinary L-FABP is a
potential biomarker for the detection and assessment of AKI
and may be useful in predicting dialysis-free survival [84].
3.8. Tubular Enzymuria. Isoforms of a variety of enzymes
released from proximal and renal tubular cells are measur-
able in the urine. These include gamma glutamyl transpep-
tidase (GGT), alkaline phosphatase, lactate dehydrogenase,
and α and π glutathione S-transferase (GST) [85–87]. It
is possible that a panel of these markers measure in the
urine could give important internal validity to not only the
presence of, but potentially the location of injury along the
nephron [88].
4.Conclusions
This paper has summarized a newly proposed framework for
CRSsinordertobetterunderstandﬁvepossiblesubtypes[3].
A description of possible heart-kidney interactions is critical
to our understanding and will guide future investigations
into pathophysiology, screening, diagnosis, prognosis, and
management. Recent studies have identiﬁed and character-
ized several novel biomarkers for CRSs. It is anticipated
that these biomarkers will help make an earlier diagnosis of
CRSs as well as identify its speciﬁc type and potentially its
pathophysiology.Ofparticularinterestistherecognitionthat
tiny amounts of poorly bound labile iron catalyze oxidative
stress reactions and further propagate organ injury. This
may be a ﬁnal common mechanism for most CRSs variants,
and thus a prime diagnostic and therapeutic target in future
clinical study. It is hoped in the future that some of these
new biomarkers including catalytic iron and the kidney’s
response, NGAL, will provide suﬃcient risk prediction and
early diagnosis to allow for prevention and treatment CRSs.
It remains to be seen whether or not eﬀective prevention
and treatment of CRSs will improve hard renal and cardiac
outcomes including ESRD, hospitalizations, and death.
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